Studies have shown that some downstream factors of the EGFR pathway, such as mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-kinase (PI3K), can adjust the high expression of VEGF, resulting in tumor progression and metastasis, and acquired EGFR-TKI resistance. This evidence concerns the gene EGFR and neoplasm.